ClinicalTrials.gg
BiologicalDrug

Lisocabtagene maraleucel clinical trials

Also written JCAR017 and Breyanzi.

studies test it
17
open now
4
in phase 3
2
first study started
2016

How each study uses lisocabtagene maraleucel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lisocabtagene maraleucel studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
5 Feb 2021 · Breyanzi · BLA 125714 (FDA, Purple Book)
European Union
4 Apr 2022 · Breyanzi · EMEA/H/C/004731 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lisocabtagene Maraleucel
9
Liso-cel
6
Anti-CD19-CAR Genetically Engineered Autologous T Lymphocytes JCAR017
3
Anti-CD19-CAR Genetically Engineered Autologous T-lymphocytes JCAR017
3
Autologous Anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T-lymphocytes JCAR017
3

Brand

Breyanzi
7

Development codes

JCAR017
10
BMS-986387
1

Studies by the year they started

17 studies that test it; most in 2018 (5)

Studies that test lisocabtagene maraleucel, by start year
YearStudies
20161
20171
20185
20201
20235
20242
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
13
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 7

Juno Therapeutics, a Subsidiary of Celgene (4) · Celgene (3) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (3) · University of Nebraska (1) · City of Hope Medical Center (1) · Patrick C. Johnson, MD (1) · Masonic Cancer Center, University of Minnesota (1) · Massachusetts General Hospital (1)

Often tested with

Tested in the same studies.

Tisagenlecleucel (2) · Axicabtagene ciloleucel (2) · Fludarabine (2) · Cyclophosphamide (2) · Ibrutinib (1) · Nivolumab (1) · Acalabrutinib (1) · Brexucabtagene autoleucel (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test lisocabtagene maraleucel.

Studies

Open first, then newest update. How each study uses lisocabtagene maraleucel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 17

Given beside what is tested · 7 — lisocabtagene maraleucel is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with lisocabtagene maraleucel

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting1

Codes

What other systems call lisocabtagene maraleucel · ClinicalTrials.gg INT015482

  • UNII (FDA) 7K2YOJ14X0LISOCABTAGENE MARALEUCELOne source FDA
  • RxNorm 2479136One source FDA
  • NCI Thesaurus C125192Lisocabtagene MaraleucelOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.